CD274 and endometrial cancer: Nivolumab (anti-PD-1), approved by the FDA; atezolizumab and durvalumab (PD-L1 inhibitors), which are currently in clinical trials; and cabozantinib, a tyrosine kinase inhibitor, are also used in the treatment of endometrial cancer.